Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

1,5-Anhydro-D-Mannitol Is a Potentially Low-Energy Carbohydrate: A Dual-Model Approach in Rats and a Randomized, Three-Way Crossover Trial in Humans.

Nutrients·2026
Same author

Comparative outcomes of umbilical cord blood transplantation versus haploidentical transplantation according to post-transplant cyclophosphamide use in adolescent and young adult patients.

Bone marrow transplantation·2026
Same author

Iron recovery dynamics after whole blood donation and the effect of low-dose iron supplementation in Japanese donors.

Vox sanguinis·2026
Same author

Effects of pre-donation salt-loading on the occurrence of delayed vasovagal reactions.

Vox sanguinis·2026
Same author

Are matched-related donors always the best choice? A retrospective study exploring the potential of umbilical cord blood.

International journal of hematology·2026
Same author

Motor Neuron Disease with Guillain-Barré Syndrome? Motor Band Sign with Anti-GQ1b Antibodies.

Diagnostics (Basel, Switzerland)·2026
Same journal

Peritransplant KMT2A-r Molecular MRD Dynamics and Relapse Timing Stratify Outcomes After Allo-HSCT in CR1 Acute Leukemia.

Transplantation and cellular therapy·2026
Same journal

Harnessing the Power of Two: High-Dose Stem Cell Haploidentical Transplant in Hematologic Malignancies - A Prospective Trial.

Transplantation and cellular therapy·2026
Same journal

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Transplantation and cellular therapy·2026
Same journal

Real-world use of maribavir for refractory CMV infection and intolerance to conventional anti-CMV agents after allogeneic hematopoietic cell transplantation.

Transplantation and cellular therapy·2026
Same journal

Do We Sin When Treating Patients with Higher-Risk Myelodysplastic Syndromes?

Transplantation and cellular therapy·2026
Same journal

The Last Mile in CAR-T Cell Therapy.

Transplantation and cellular therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Adjusting Disease Risk Index for Regional Variations and Donor Selection.

Makoto Iwasaki1, Yachiyo Kuwatsuka2, Hiromi Hayashi1

  • 1Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Transplantation and Cellular Therapy
|June 6, 2026
PubMed
Summary
This summary is machine-generated.

A new region-adjusted Disease Risk Index (raDRI) improves prognostic accuracy for hematopoietic stem cell transplantation (HSCT). The raDRI guides donor selection, showing matched related donors improve survival in low-risk patients.

Keywords:
Disease risk indexDonor sourceMatched related donorPeripheral T-cell lymphomaRegional distribution

Related Experiment Videos

Last Updated: Jun 8, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Biostatistics

Background:

  • The Disease Risk Index (DRI) is a standard prognostic tool for hematopoietic stem cell transplantation (HSCT).
  • The refined DRI (rDRI) has limitations in accounting for regional variations in disease prevalence and treatment strategies.

Purpose of the Study:

  • To refine the rDRI by incorporating underrepresented disease entities and regional HSCT treatment differences.
  • To develop a region-adjusted DRI (raDRI) and identify optimal donor selection strategies based on new risk criteria.

Main Methods:

  • Analyzed 7,720 patients undergoing first allogeneic HSCT (2014-2016) using Japanese registry data to develop the raDRI.
  • Validated the raDRI's predictive performance in a separate cohort of 5,108 patients transplanted (2017-2018).

Main Results:

  • The raDRI demonstrated superior predictive accuracy over the rDRI (AUC: 0.705 vs. 0.670).
  • In low-to-intermediate risk patients (raDRI), matched related donors (MRD) improved overall survival compared to matched unrelated donors.
  • No significant survival differences were observed between MRD and matched unrelated donors in high-risk patients.

Conclusions:

  • Prognostic indices like the DRI are influenced by the specific populations and clinical practices of their origin.
  • Regional variations in disease prevalence, treatment, and donor selection significantly impact HSCT risk stratification and outcomes.
  • The developed raDRI offers improved risk assessment and informs donor selection strategies in HSCT.